Merck signs $356M deal to supply US with experimental coronavirus drug

The U.S. government will pay Merck & Co. $356 million for between 60,000 and 100,000 doses of an experimental drug being tested as a treatment of gravely ill patients hospitalized with COVID-19. Merck acquired the drug, dubbed MK-7110, in a $425 million buyout of the biotech OncoImmune last month.